| Jun 18 |
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
|
| Jun 17 |
Mirum stock climbs after positive interim data from liver disease drug
|
| Jun 17 |
Mirum Pharmaceuticals Advances after Reporting Positive Trial Results for Prospective Cholangitis Treatment
|
| Jun 17 |
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
|
| Jun 16 |
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
|
| Jun 7 |
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
|
| Jun 6 |
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
|
| Jun 5 |
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| Jun 3 |
EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC
|
| May 31 |
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
|
